Dr Miles graduated with a BSc (hons) in Biomedical Science at Nottingham Trent University (1996-2000), followed by a PhD (Molecular Cancer Biology) in the same department sponsored by the John and Lucille van Geest Foundation from 2000 to 2004. The PhD was entitled "The identification and characterisation of novel tumour antigens".
From 2008-2012 Dr Miles then transferred her skills and became project lead for the identification of novel tumour antigens as immunotherapeutic targets. This role involved the in vitro screening of multiple cDNA expression libraries to identify potential immunogenic tumour antigens. Robust transcriptomic analysis of the antigens and subsequent protein expression analysis using IHC.
In 2012 Dr Miles became Senior Research Fellow and project lead for the development of novel beta bloc kers as adjuvant t herapies for breast cancer. This role involves the design and timely execution of in vitro methodologies to investigate the potential role of these compounds in preventing breast cancer metastasis. The project involves cross disciplinary collaborations with the Department of Chemistry at NTU and Nottingham University Hospitals NHS Trust.
Dr Miles now leads ChemPartner’s work with clients on cancer research and helps run our Copenhagen facility and our presence in the EU. She believes in strong cross-team collaboration and embedded partnerships drive faster and more rigorous breakthroughs for our clients.
In 2012 Dr Miles became Senior Research Fellow and project lead for the development of novel beta bloc kers as adjuvant t herapies for breast cancer. This role involves the design and timely execution of in vitro methodologies to investigate the potential role of these compounds in preventing breast cancer metastasis. The project involves cross disciplinary collaborations with the Department of Chemistry at NTU and Nottingham University Hospitals NHS Trust.
Dr Miles now leads ChemPartner’s work with clients on cancer research and helps run our Copenhagen facility and our presence in the EU. She believes in strong cross-team collaboration and embedded partnerships drive faster and more rigorous breakthroughs for our clients.
- Tumor Antigen Identification
- Urological Cancer Targeted Treatments
- In Vivo Pharmacology
- Safety Pharmacology & Neurotoxicology
- Pharmacokinetics & CNS Drug Delivery
- IND-Enabling Study Leadership
- Preclinical Model Design & Validation
- Translational Neuroscience & Biomarkers
- Regulatory Strategy for CNS Therapeutics
- Data Integration & Decision-Making
Selected Publications
Meet Our
People